Abstract | BACKGROUND: METHODS: Patients with advanced ACC were included in this phase II trial investigating the response to a combination of cisplatin (50 mg m(-2)) and docetaxel (60 mg m(-2)) administered with a 3-week interval. RESULTS: Nineteen patients were included in this study. The response rate was 21% (95% CI: 3-39%). No patients obtained a complete response, 32% had stable disease, and 37% progressed while on treatment. The median progression-free survival (PFS) was 3 months (95% CI: 0.7-5.3 months) and 1 year PFS was 21% (95% CI: 3-39%). Median survival was 12.5 months (95% CI: 6-19 months). The predominant grade 3/4 toxicity was neutropenia (35%); febrile neutropenia occurred in 5% of cycles. CONCLUSION: This study could not demonstrate that the combination of cisplatin and docetaxel has higher efficacy than other regimens reported in previous studies.
|
Authors | T Urup, W Z Pawlak, P M Petersen, H Pappot, M Rørth, G Daugaard |
Journal | British journal of cancer
(Br J Cancer)
Vol. 108
Issue 10
Pg. 1994-7
(May 28 2013)
ISSN: 1532-1827 [Electronic] England |
PMID | 23652308
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Taxoids
- Docetaxel
- Cisplatin
|
Topics |
- Adrenal Cortex Neoplasms
(drug therapy, mortality, pathology)
- Adrenocortical Carcinoma
(drug therapy, mortality, pathology)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Cisplatin
(administration & dosage, adverse effects)
- Disease Progression
- Docetaxel
- Female
- Humans
- Male
- Middle Aged
- Survival Analysis
- Taxoids
(administration & dosage, adverse effects)
- Treatment Outcome
- Young Adult
|